SureTrader Nadex Advertisement SureTrader
Home > Boards > US OTC > Medical - Healthcare >

Theralase Technologies Inc. (TLTFF)

Add TLTFF Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 4/27/2017 10:59:29 AM - Followers: 61 - Board type: Free - Posts Today: 0


Jan 22, 2014 7:20 AM | about stocks: TLTFF


Theralase Technologies Inc. (TSX-V: TLT, US-OTCBB: TLTFF). They design, develop, manufacture and market, patented, super-pulsed laser technology used in biostimulative and biodestructive clinical applications. The Theralase technology platform targets several health-care sectors: First, for non-invasive pain management and clinical therapy, used in neural muscular skeletal conditions, including arthritis and osteoarthritis; Second, wound care and healing (including non-healing fractures and bone fracture regeneration); And third, research and development into combining patented photodynamic compounds (PDCs) with patented, super-pulsed, biofeedback laser technology to attack specifically targeted cancers, bacteria and viruses.

The company is currently focused on the commercialization (production, marketing and distribution) of the TLC-2000 Superpulsed Laser Technology to healthcare practitioners, and commercialization of the patented TLC-3000 Photo Dynamic Compound Cancer Technology through pre-clinical research and clinical trials.

Key Investment Highlights:

  • Working on breakthrough bladder cancer destruction technology and has achieved tremendous success in pre-clinical trials
    Proven clinical technology (TLC-1000) and commercial therapeutic laser business and brand developed over last 17 years, currently generating ~2M of revenue annually
    Rollout of new TLC-2000 technology in 2014, along with a new recurring revenue business model
    Strategic agreements in place with world renowned institutions to help advance research and mitigate expenses
    Competitive technical advantages (Cellular pathways: iNOS, ATP, Na+ / K+)
    Future technology (patented biofeedback technology and patented PDC cancer destruction)
    IP protection (multiple issued patents)
    Large addressable US markets ($ billions)
    No debt
    Positive cash flow / double digit growth
    Lots of opportunity for short-term and long-term growth (revenue & profit)
    Experienced management team (20+ years)
    Clear vision and execution strategy


Theralase has patented anti-cancer drugs known as Photo Dynamic Compounds (PDCs) which localize the DNA of cancer cells and when irradiated, destroy the DNA resulting in apoptosis (natural cell death). While PDCs are used in Photodynamic Therapy (PDT) as a potential treatment regime for a number of conditions, Theralase has discovered that they hold particular promise as treatment to particular cancers. Theralase PDCs have proven successful in destroying breast, colon, brain and bladder cancer cells. Recent lab results have shown that Theralase was able to completely destroy subcutaneous bladder cancer tumors in mouse models. "The achievement of this important milestone signifies that Theralase's leading drug candidate is effective in the destruction of cancer in a live animal model and can prevent the cancer from recurring," commented Roger White of Theralase.

Key Market Statistics:

  • US bladder cancer treatment annual spending was $3.9 billion in 2012
    70,000 new cases, > 14,000 deaths in the US each year
    386,000 new cases are diagnosed worldwide annually
    Standard treatment unchanged with no new drugs approved since 1998
    5th most common cancer, 4th in men, 8th in women
    Most expensive cancer to treat with a recurrence rate up to 80%
    70% of new bladder cancer cases are early stage disease and 90% of bladder cancers are Transitional Cell Carcinoma (TCC)

Theralase PDC Characteristics:

  • Up to 100% cancer cell kill at very low concentrations (< 0.8μM)

(click to enlarge)

  • More effective at killing cancer cells than FDA approved drugs

(668,000x ALA, 198x PHOTOFRIN)

  • Survival of mice up to 20 months (50 human years) after one Theralase PDT treatment

(click to enlarge)

We are VERY IMPRESSED, and VERY EXCITED about these results! In 2012, annual spending for bladder cancer treatment in the US was $3.9 billion, and the current standard of care has been unchanged with no new drugs approved since 1998. Bladder cancer is the most expensive cancer to treat, and has a recurrence rate up to 80%. All of the mice which showed an initial response have remained cancer free, healed without scarring, and have developed normally after only one Theralase PDC treatment. Needless to say, the early results from Theralase look extremely positive. Imagine being able to not only provide treatment for bladder cancer, but to actually cure it, and stop it from coming back! The company is also working on developing further PDCs that can be used to treat a wide variety of other cancers (breast, colon, brain and lung), as well as bacteria and viruses.

  • The general patent protects 1,000s of molecules - essentially a library of PDCs
    Virtually 0% toxicity at high concentrations (> 100μM) leading to ultra-high safety profile
    Activated by laser light providing excellent specificity and selectivity
    Able to treat solid core hypoxic tumors, such as: breast, prostate and lung
    Research outsourced to and performed at world renowned Princess Margaret Cancer Centre
    Patented under numerous US and International Patents:
    Issued USA Patents: 6,962,910, 7,612,057, 8,148,360, 8,445,475
    Pending USA Patent Applications: 61/801,674, 13/863,089, 13/36595

To help explain how the procedure works we sketched a diagram:

(click to enlarge)

  1. A catheter is inserted into the patient
    The PDC is injected and saturates within the patient's bladder, penetrating the cellular membrane (DNA localizing)
    Fiber optics cables are inserted up the catheter into the bladder
    Using laser technology, light is irradiated 360°
    The entire procedure takes about 2 - 3 hours

Theralase is currently completing the validation of the orthotopic rat model, a dose toxicity study, GMP drug manufacture, and FDA Investigational New Drug (IND) application. The next phase is to complete an FDA phase 1/2a human clinical study with FDA breakthrough status, and then to execute a strategic partnership agreement with big pharmaceutical (pharma) company (upfront payments, co-development funds, annual recurring revenue streams).

Industry comparables:

(click to enlarge)

(click to enlarge)

Deals with comparable big pharma companies have yielded anywhere from $466M to $1B plus royalties.


The thing is, by the time clinical trials have been completed (assuming they're successful), Theralase will be trading many multiples higher than today. Look how excited investors got when Theralase first released PDC breast cancer results during January 2010, the intraday high for TLT was $1.39/share:

Read More :

Themes: Biotechnology, Micro Capitalization, Growth Opportunity, Pharmaceuticals, Cancer, Laser Technology, Photo Dynamic Compounds (PDCs) Stocks: TLTFF
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
TLTFF News: Theralase Demonstrates 18 Month Stability of Lead Anti-Cancer Drug 03/15/2017 07:02:00 AM
TLTFF News: Theralase Anti-Cancer Technology Picks Up Steam 01/06/2015 07:00:00 AM
TLTFF News: Theralase CEO to Be Interviewed Today on Clear Channel Business Talk Radio DFW 1190AM 03/12/2014 07:05:00 AM
TLTFF News: Theralase Achieves Commercialization Milestone For Its Bladder Cancer Therapy 03/14/2013 07:00:04 AM
#2779   I posted on Stockhouse that the fact that Harpos 04/27/17 10:59:29 AM
#2778   CFO Kristina Hachey is Roger's wife for those Harpos 04/27/17 10:55:35 AM
#2777   Lol r/s What garbage We will spike to $3-5 How? MIKE22CA 04/27/17 07:37:28 AM
#2776   There is a "visit window" for each subject Geo2014 04/25/17 01:35:20 PM
#2775   settle down, it was a surmising, we all bc2602 04/25/17 01:30:35 PM
#2774   First of all, a reverse split in NOT SurgGuy 04/25/17 12:45:14 PM
#2773   Wouldn't want to see a r/s - I MasterSalix 04/25/17 11:48:16 AM
#2772   I'd love to see us get to a bc2602 04/25/17 11:33:55 AM
#2771   We probably have some consolidating to do today bc2602 04/25/17 11:30:38 AM
#2770   Will we see .40 today? abun 04/25/17 09:38:09 AM
#2769   Hospitals can do scans whenever they want. MIKE22CA 04/25/17 09:20:32 AM
#2768   Weekend? Probably Monday, no? CUIN2 04/25/17 07:19:17 AM
#2767   First bladder CT scan this weekend. First MIKE22CA 04/25/17 07:15:07 AM
#2766 123414 04/24/17 07:29:04 PM
#2765   Sure would be nice. Feels exciting abun 04/24/17 05:07:03 PM
#2764   are we about to make history? heavymetal 04/24/17 04:55:59 PM
#2763   Heard also the CFO recently plucked down 50,000 MasterSalix 04/24/17 04:19:29 PM
#2762   This is the clinical trial page that shows SurgGuy 04/24/17 03:06:35 PM
#2761   This rise in volume and price coincides with SurgGuy 04/24/17 03:03:54 PM
#2760   Someone must know something going on behind the SurgGuy 04/24/17 01:04:18 PM
#2759   Are u aware of PDTs endpoints? The value wont MIKE22CA 04/23/17 05:12:53 PM
#2758   Things are sure moving in the right direction MasterSalix 04/23/17 10:30:50 AM
#2757   Well theres a gap in treatment dates so MIKE22CA 04/23/17 09:01:48 AM
#2755   oops, rapped = wrapped heavymetal 04/23/17 08:22:25 AM
#2754   there is a package, all rapped up with heavymetal 04/23/17 07:27:43 AM
#2753   I'm guessing that somehow the market will find CUIN2 04/22/17 10:06:16 PM
#2752   You're right! Although I don't believe they'll come Anesthesia 2007 04/20/17 03:49:47 PM
#2751   Remember it's April 29 for the first patient... MIKE22CA 04/20/17 02:58:33 PM
#2750   At least now we can count 30 days Anesthesia 2007 04/20/17 11:52:03 AM
#2749   Fantastic news!!! CUIN2 04/20/17 11:37:59 AM
#2748   Hopefully things are looking up! Theralase PDT Technology Used Anesthesia 2007 04/20/17 11:34:50 AM
#2747   Family and friends? CUIN2 04/20/17 08:06:59 AM
#2746   Interesting, with yesterday's spike in share price - SurgGuy 04/20/17 08:03:30 AM
#2745   This implies (in my mind at least) that CUIN2 04/18/17 04:23:12 PM
#2744   AccesswireApril 18, 2017 TORONTO, ON / ACCESSWIRE / April CUIN2 04/18/17 03:50:10 PM
#2743   Theralase Grants Stock Options Accesswire AccesswireApril 18, 2017 TORONTO, ON CUIN2 04/18/17 09:08:53 AM
#2742   We're treated a post 'scraped' bladder of any MIKE22CA 04/14/17 03:51:36 PM
#2741   The Theralase PDCs have shown up to a 123414 04/14/17 11:57:12 AM
#2740   light is the catalyst. heavymetal 04/13/17 07:12:21 AM
#2739   Like sunlingt can destroy germs and disinfect. Light 123414 04/13/17 06:12:11 AM
#2738   Good day and more to come IMO CUIN2 04/12/17 05:49:04 PM
#2737   those of us who understand what may be heavymetal 04/12/17 03:55:49 PM
#2736   This is the period of silence just like MIKE22CA 04/12/17 02:45:54 PM
#2735   Theralase Affiliated Researchers to Present at International Conference Accessw CUIN2 04/12/17 11:12:06 AM
#2734   The upcoming GBM report. Will it contain additional Gene_Simmons 04/12/17 09:34:15 AM
#2733   Any thoughts on when 2016 year end financials CUIN2 04/11/17 12:11:02 PM
#2732   i think i heard in on the grapevine. heavymetal 04/11/17 10:12:56 AM
#2731   That should be "treatment"...sorry, maternal language is dutch! Big Pharma 04/11/17 09:59:47 AM
#2730   How do you know that a second patient Big Pharma 04/11/17 09:56:59 AM
#2729   since we know a second patient has started heavymetal 04/11/17 08:50:15 AM